Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · IEX Real-Time Price · USD
1.446
+0.036 (2.55%)
Apr 23, 2024, 12:48 PM EDT - Market open
Clearside Biomedical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CLSD stock have an average target of 5.00, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 245.78% from the current stock price of 1.45.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
The average analyst rating for CLSD stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +314.94% | Mar 14, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +245.78% | Mar 13, 2024 |
| Wedbush | Wedbush | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +176.63% | Mar 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +176.63% | Mar 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +314.94% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
2.41M
from 8.23M
Decreased by -70.71%
Revenue Next Year
7.90M
from 2.41M
Increased by 227.98%
EPS This Year
-0.54
from -0.53
EPS Next Year
-0.57
from -0.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.1M | 16.9M | 37.5M | 126.5M | 214.8M |
| Avg | 2.4M | 7.9M | 22.5M | 78.3M | 145.5M |
| Low | n/a | n/a | 9.4M | 53.8M | 104.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.7% | 603.3% | 374.9% | 461.1% | 174.2% |
| Avg | -70.7% | 228.0% | 185.3% | 247.5% | 85.8% |
| Low | - | - | 19.1% | 138.7% | 33.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.48 | -0.46 | -0.22 | 0.78 | 1.72 |
| Avg | -0.54 | -0.57 | -0.65 | 0.21 | 1.07 |
| Low | -0.62 | -0.65 | -1.06 | -0.32 | 0.45 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 723.5% |
| Avg | - | - | - | - | 412.2% |
| Low | - | - | - | - | 115.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.